2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Join Dr. Edward Kim, Dr. Mohamed Mohamed, and Dana Herndon, RN, in a live broadcast to learn more about the current treatment landscape of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).
Lung cancer is the leading cause of cancer-related death in the United States.1 About 13% of all lung cancer cases in the United States are small cell lung cancer (SCLC), and most patients are diagnosed with extensive-stage (ES)-SCLC.2,3 The prognosis for patients with SCLC is poor, with an overall 5-year survival rate of 6% and just 3% among those with distant metastasis.2
Systemic chemotherapy in combination with immune checkpoint inhibitors is the standard of care for patients with ES-SCLC.4 However, these regimens present a treatment challenge due to multilineage myelosuppression. Myelosuppression increases a patient’s risk for bleeding complications, infections, and secondary malignancies,5 and is the most common reason for dose reductions, delays, and discontinuation of chemotherapy.
Join Dr. Kim, Dr. Mohamed, and Dana Herndon, RN, in a live broadcast to learn more about the current treatment landscape of chemotherapy-induced myelosuppression in patients with ES-SCLC. These leading experts will discuss the clinical data, safety, and considerations of a therapeutic option for chemotherapy-induced myelosuppression.